Your browser is no longer supported. Please, upgrade your browser.
IBIO iBio, Inc. daily Stock Chart
IBIO [AMEX]
iBio, Inc.
Index- P/E- EPS (ttm)-1.18 Insider Own1.20% Shs Outstand143.88M Perf Week-3.00%
Market Cap667.60M Forward P/E- EPS next Y- Insider Trans-7.11% Shs Float109.49M Perf Month130.61%
Income-39.20M PEG- EPS next Q- Inst Own8.50% Short Float2.69% Perf Quarter318.52%
Sales1.30M P/S513.54 EPS this Y38.70% Inst Trans2.83% Short Ratio0.12 Perf Half Y1561.76%
Book/sh0.05 P/B90.40 EPS next Y- ROA-108.70% Target Price- Perf Year545.71%
Cash/sh0.07 P/C66.76 EPS next 5Y- ROE- 52W Range0.05 - 7.45 Perf YTD1715.26%
Dividend- P/FCF- EPS past 5Y-10.10% ROI-57.60% 52W High-39.33% Beta-5.51
Dividend %- Quick Ratio1.70 Sales past 5Y58.00% Gross Margin- 52W Low8940.00% ATR0.78
Employees7 Current Ratio1.70 Sales Q/Q-80.00% Oper. Margin- RSI (14)57.39 Volatility16.21% 19.53%
OptionableYes Debt/Eq8.40 EPS Q/Q73.40% Profit Margin- Rel Volume0.39 Prev Close4.44
ShortableYes LT Debt/Eq8.03 Earnings- Payout- Avg Volume25.15M Price4.52
Recom- SMA2015.44% SMA5076.82% SMA200302.72% Volume9,769,399 Change1.80%
Jun-26-20Initiated Alliance Global Partners Buy $2.55
Jul-20-20 10:17AM  
Jul-10-20 03:19PM  
11:24AM  
Jul-02-20 01:56PM  
Jun-27-20 11:55AM  
Jun-26-20 02:32PM  
11:48AM  
08:18AM  
06:45AM  
Jun-24-20 06:45AM  
Jun-18-20 10:50PM  
Jun-05-20 06:01AM  
Jun-04-20 07:00AM  
May-29-20 09:10AM  
May-27-20 11:45AM  
May-22-20 09:05AM  
May-21-20 02:44PM  
Apr-28-20 03:44PM  
Apr-27-20 04:15PM  
Apr-24-20 07:00AM  
Apr-09-20 07:30AM  
Apr-03-20 05:01AM  
Mar-26-20 04:20PM  
07:30AM  
Mar-20-20 11:38AM  
07:30AM  
Mar-18-20 08:00AM  
Mar-13-20 08:08AM  
Mar-12-20 04:45PM  
Mar-05-20 04:20PM  
08:07AM  
Mar-02-20 04:30PM  
Feb-28-20 10:12AM  
Feb-17-20 08:52AM  
Feb-06-20 04:30PM  
Feb-04-20 08:54AM  
Feb-03-20 04:15PM  
Jan-16-20 08:00AM  
Jan-06-20 09:15AM  
Dec-23-19 09:30AM  
08:30AM  
Dec-19-19 11:22AM  
Dec-16-19 04:15PM  
Dec-13-19 05:00PM  
Dec-10-19 04:44PM  
Dec-03-19 12:31PM  
Dec-02-19 04:15PM  
Oct-25-19 08:30AM  
Oct-22-19 04:30PM  
Sep-19-19 01:58PM  
Sep-17-19 04:15PM  
Aug-26-19 05:30PM  
Aug-21-19 12:15PM  
Aug-19-19 04:35PM  
Jul-25-19 11:16AM  
Jun-19-19 08:00AM  
Jun-10-19 01:58PM  
Jun-03-19 08:00AM  
Apr-24-19 02:03PM  
Apr-01-19 08:30AM  
Dec-14-18 08:00AM  
Dec-03-18 08:00AM  
Oct-02-18 08:00AM  
Aug-22-18 04:10PM  
Jul-09-18 08:00AM  
Jun-27-18 07:20AM  
Jun-26-18 06:59PM  
Jun-22-18 07:26AM  
Jun-08-18 04:30PM  
04:01PM  
Jun-05-18 08:30AM  
Jun-04-18 05:46PM  
May-31-18 08:30AM  
May-24-18 07:15AM  
Apr-11-18 01:27PM  
Mar-14-18 08:30AM  
Mar-12-18 08:30AM  
Mar-07-18 08:45AM  
Dec-18-17 03:44PM  
Dec-08-17 02:53PM  
01:03PM  
Nov-30-17 04:15PM  
Nov-29-17 09:00AM  
Nov-28-17 05:07PM  
Nov-27-17 02:12PM  
Nov-14-17 02:27PM  
Nov-13-17 09:20AM  
Nov-08-17 12:00PM  
Nov-06-17 05:00PM  
Oct-30-17 08:30AM  
Oct-24-17 09:39AM  
Oct-23-17 08:00AM  
Oct-18-17 07:00AM  
Oct-16-17 07:15AM  
07:15AM  
Oct-13-17 10:56AM  
Oct-05-17 05:36PM  
Oct-04-17 09:00AM  
Oct-02-17 10:54AM  
08:30AM  
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of pre-clinical development, regulatory approval, commercial product launch, and on-going commercial phase requirements. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. The company is also developing vaccine candidates for third parties. It has a license agreement with the University of Natural Resources and Life Sciences, Vienna; a strategic relationship with Beijing CC-Pharming Ltd.; and collaboration agreements with AzarGen Biotechnologies (Pty) Ltd, The Texas A&M University System, and Fraunhofer Center for Molecular Biotechnology. In addition, the company offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ERWIN ROBERT LPresidentJun 04Option Exercise0.9328,26826,289108,108Jun 08 12:41 PM
ERWIN ROBERT LPresidentJun 04Sale1.7128,26848,338108,108Jun 08 12:41 PM
ERWIN ROBERT LPresidentJun 02Option Exercise0.9396,12489,395136,376Jun 05 06:04 AM
ERWIN ROBERT LPresidentJun 02Sale1.6296,124155,721136,376Jun 05 06:04 AM
Mullaney James P.Chief Financial OfficerMay 27Option Exercise0.9311,25010,4630May 29 12:45 PM
Mullaney James P.Chief Financial OfficerMay 27Sale1.6111,25018,1130May 29 12:45 PM